Your browser doesn't support javascript.
loading
Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease Hospitalizations in Japan Before and After the Introduction of a Heated Tobacco Product.
van der Plas, Angela; Antunes, Meagan; Romero-Kauss, Alba; Hankins, Matthew; Heremans, Annie.
Afiliação
  • van der Plas A; PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
  • Antunes M; PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
  • Romero-Kauss A; PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
  • Hankins M; PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
  • Heremans A; PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Front Public Health ; 10: 909459, 2022.
Article em En | MEDLINE | ID: mdl-35836991
ABSTRACT
To substantiate the beneficial effects of switching from cigarette smoking to heated tobacco products (HTP), this study conducted a time-trend analysis using data from the Japanese Medical Data Center (JMDC) database. Specifically, we assessed hospitalization numbers for chronic obstructive pulmonary disease (COPD) exacerbations and acute ischemic heart disease (IHD) before and after the introduction of HTPs in the Japanese market. This study replicated a previous study using a different Japanese real-world data source (Medical Data Vision). We retrieved the number of hospitalizations associated with the International Classification of Diseases-10 codes for COPD and IHD from 2010 to 2019-5 years before to 4 years after introducing HTPs in the Japanese market-from the JMDC database. Then, we used interrupted time-series analyses to test the hypothesis that the introduction of HTPs is associated with a reduction in hospitalizations for COPD (all codes), COPD exacerbation, COPD exacerbation plus lower respiratory tract infections (LRTI), and IHD, adjusting for age, sex, seasonality, and flu vaccination rates. Analysis of all available data from the JMDC database revealed a significant reduction in the number of hospitalizations for COPD (all codes; P = 0.0001) and IHD using Diagnosis Procedure Combination data on causative disease flags (P < 0.00001). We also observed a non-significant reduction in hospitalizations for COPD plus LRTI as well as IHD after HTP introduction in Japan. This study confirmed the findings of our previous study where a decrease in hospitalizations due to COPD exacerbation after the introduction of HTPs in Japan was also shown. Nevertheless, these findings warrant further research to evaluate the impact of HTPs on the health of populations in other countries where these products have been introduced.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isquemia Miocárdica / Doença Pulmonar Obstrutiva Crônica / Produtos do Tabaco Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Front Public Health Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isquemia Miocárdica / Doença Pulmonar Obstrutiva Crônica / Produtos do Tabaco Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Front Public Health Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça